bio quotes
We continue to see ourselves as diabetes
leader. At that same time, we are ready to
take important plunge into other key areas.
We have good oncology portfolio and we
also plan to launch three more products in
next two or three years in India. New areas
where we plan to concentrate in a big way
are Rheumatoid Arthritis and Psoriasis Given the highly skilled talent,
technological capabilities and
experience available in India, we are
uniquely positioned to emerge as a
leading destination in the delivery of
these services to global companies
Vaccines face a tougher safety standard
than biosimilars due to their likely
toxic effects, especially on children
and people with immune deficiency.
Therefore, regulatory authorities
have become increasingly vigilant Nearly 80 percent of the global population
still relies on traditional herbal therapies
for primary healthcare, according to the
World Health Organization. Along with
this demand comes a need for continuous
supply of high quality raw materials
Edgard A. Olaizola, Managing
Director, Eli Lilly India
Mandar Athalekar, Market &
Product Development Leader-
South Asia, Thomson Reuters
104
BioVoiceNews | August 2017
Naz Haji, Senior Vice President &
CRO Head-India, QuintilesIMS
Dr Muhammed Majeed, Founder
& Chairman, Sami Labs